Spark Therapeutics and Pfizer report preliminary data from hemophilia B phase 1/2 trial
Spark Therapeutics and Pfizer announced updated preliminary dat from the first nine infused participants in the ongoing Phase 1/2 clinical trial of investigational SPK-9001 for hemophilia B, who received a single administration of 5 x 1011 vector genomes (vg)/kg body weight. December 03, 2016